newsfilter
← Latest News
Business Wire·

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

EQ

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30, 2024, the